Roy Orden, MD
Allergy · Walnut Creek, CANPI 1861781056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 637 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations.
Across 637 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$970
- Alk-abello, Inc$714
- plus $7K from 33 others
Across 9 payments — averaging $4078.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Optinose US, Inc.$37K
Across 2 payments — averaging $2445.53 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$5K
What the payments were for
- Consulting fees$9136%
- Food & beverage$14,63793%
- Education$1791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,729 in reported general payments places this provider in the 80th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $48,450 |
| CinqairReslizumab | 11 | $35,579 |
| XolairOmalizumab | 15 | $27,568 |
| Spiriva RespimatTiotropium Bromide | 30 | $19,408 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $13,482 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,154 |
| DuleraMometasone/Formoterol | 13 | $6,204 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,738 |
| Epinephrine | 25 | $4,079 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,437 |
| Ipratropium Bromide | 80 | $2,365 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $2,234 |
| Azelastine Hcl | 67 | $1,782 |
| Montelukast Sodium | 114 | $1,529 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 13 | $1,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,942 | $58,60472 claims |
| Teva Pharmaceuticals USA, Inc.Cinqair | $343 | $35,57911 claims |
| Genentech, Inc.Xolair | $68 | $27,56815 claims |
| Boehringer IngelheimSpiriva Respimat | $516 | $19,40830 claims |
| MerckDulera | $17 | $6,20413 claims |
| AstraZenecaSymbicort | $2,104 | $4,73815 claims |
| Hikma Pharmaceuticals USAEpinephrine | $71 | $4,07925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 117 allergy providers in California.
Other allergy in Walnut Creek
- Joshua JacobsWalnut Creek$1.5M
- Kelsey IgeWalnut Creek$7K
- Shilpi AnandWalnut Creek$5K
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.